Path .

XBI falls as investors, biotech CEOs weigh whether approval bar will rise

Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more

An analysis of the targets companies are pursuing to retain muscle while losing fat

Public health groups, industry trying to counter flood of anti-vaccine messaging — including from Trump administration officials

Silent leadership, FDA cuts and lack of public trust are cracking biotech’s foundations — Editor’s Commentary

Structured deal could double the payout to Regulus’ shareholders if microRNA therapy, headed for Phase III testing in ADPKD, wins U.S. approval

The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity

An advancing wave of new candidates, spanning diverse modalities, converges with push for surrogate endpoint status

Combining disparate functions will dilute expertise, adding to problems caused by staffing cuts and poor morale

FDA commissioner says pathway will offer ‘conditional’ approval in very rare diseases